![](https://canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZVk9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--2c971516a0135995552100bf2ca4b1d8d51fd56f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/peninsulapharmaceuticals.png)
Peninsula Pharmaceuticals
Peninsula Pharmaceuticals develops new antibiotic medications to treat life-threatening infections.
Partner
Brent AhrensInvestment
Series B
Peninsula Pharmaceuticals develops new antibiotic medications to treat life-threatening infections.
Series B